Shares of Invitae NVTA fell 9.39% in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share fell 48.08% over the past year to ($0.77), which missed the estimate of ($0.70).
Revenue of $46,191,000 declined by 13.62% from the same period last year, which beat the estimate of $39,620,000.
Guidance
Invitae hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Aug 04, 2020
Time: 04:30 PM
Technicals
52-week high: $35.33
52-week low: $7.42
Price action over last quarter: Up 93.14%
Company Overview
Invitae Corp operates as a genetic information company in diagnostic and research industry. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders and other hereditary conditions.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.